- Home
- Products
- Anti-Ab ADCs
- IgG Fc
- Protein G-VC-MMAE ADC
Protein G-VC-MMAE ADC (CAT#: ADC-AA-048)
This ADC product is comprised of a Protein G conjugated via a VC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IgG Fc
- Overview
- The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.
- Overview
- Protein G
- Name
- VC (valine-citrulline)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE (Monomethyl auristatin E)
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-MIgG(Fc)-C-PBD ADC (CAT#: ADC-AA-058)
- Anti-HIgG(Fc)-C-PBD ADC (CAT#: ADC-AA-059)
- anti-RIgG(HL)Fab-N-MMAF ADC (CAT#: ADC-AA-037)
- Protein G-MCC-DM1 ADC (CAT#: ADC-AA-050)
- anti-Rat IgG(Fc)Fab-C-DMDM ADC (CAT#: ADC-AA-044)
- anti-HIgG(Fc)-N-DM1 ADC (CAT#: ADC-AA-008)
- Anti-MIgG (clone HB43)-VC-MMAE ADC (CAT#: ADC-AA-057)
- anti-MIgG(Fc)-N-MMAF ADC (CAT#: ADC-AA-019)
- anti-Rat IgG(Fc)Fab-N-MMAF ADC (CAT#: ADC-AA-041)
- anti-HIgG(Fab)-N-DM1 ADC (CAT#: ADC-AA-018)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-AA-048. Click the button above to contact us or submit your feedback about this product.
Customer Reviews
FAQ
Excellent
The Protein G-VC-MMAE ADC has been a game-changer for our research. Its ability to target cancer cells specifically and efficiently makes it an invaluable tool. Highly recommend!
Excellent
This ADC product offers an economical and efficient alternative for pre-screening monoclonal antibodies. Its lack of obvious toxicity without a primary antibody is a significant advantage.
Excellent
We've seen remarkable results using Protein G-VC-MMAE ADC in our studies. The targeted delivery of MMAE and subsequent cell death in cancer cells is impressive.
Excellent
The conjugation of Protein G with VC linker to MMAE works perfectly for our cancer research. It's efficient and shows no toxicity, making it safe and reliable.
Excellent
The receptor-mediated endocytosis feature of this ADC product ensures precise targeting and delivery of MMAE into cancer cells, which is critical for our experiments.
Excellent
The functionality and effectiveness of Protein G-VC-MMAE ADC in disrupting microtubule dynamics and inducing cell death have significantly advanced our research. Great product from Creative Biolabs!
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-AA-029 | anti-MIgG(Fc)Fab-C-MMAE ADC | Cleavable linkers | MMAE (Monomethyl auristatin E) |
| ADC-AA-027 | anti-MIgG(Fc)Fab-N-MMAF ADC | Noncleavable linkers | MMAF (Monomethyl auristatin F) |
| ADC-AA-026 | anti-MIgG(Fc)-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-AA-054 | Protein A-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-AA-028 | anti-MIgG(Fc)Fab-C-MMAF ADC | Cleavable linkers | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-486 | Anti-CD37-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-529 | Anti-F3 (TF-011)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-462 | Anti-GPNMB-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-565 | Anti-EDNRB-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-564 | Anti-MUC16-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| CAT# | Product Name | Linker | Payload |
| ADC-AA-029 | anti-MIgG(Fc)Fab-C-MMAE ADC | Cleavable linkers | MMAE (Monomethyl auristatin E) |
| ADC-AA-017 | anti-HIgG(Fab)-C-MMAE ADC | Cleavable linkers | MMAE (Monomethyl auristatin E) |
| ADC-W-564 | Anti-MUC16-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-536 | Anti-EDNRB (endothelin B)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-AA-056 | Anti-MIgG (clone 187.1)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
